West Pharmaceutical Services Inc (WST)
313.66
-24.46
(-7.23%)
USD |
NYSE |
Nov 15, 16:00
310.24
-3.42
(-1.09%)
After-Hours: 20:00
West Pharmaceutical Services Research and Development Expense (Quarterly): 15.50M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 15.50M |
| June 30, 2024 | 17.50M |
| March 31, 2024 | 17.60M |
| December 31, 2023 | 18.40M |
| September 30, 2023 | 16.40M |
| June 30, 2023 | 16.50M |
| March 31, 2023 | 17.10M |
| December 31, 2022 | 15.90M |
| September 30, 2022 | 13.60M |
| June 30, 2022 | 14.40M |
| March 31, 2022 | 14.60M |
| December 31, 2021 | 13.70M |
| September 30, 2021 | 13.10M |
| June 30, 2021 | 13.80M |
| March 31, 2021 | 12.20M |
| December 31, 2020 | 12.90M |
| September 30, 2020 | 12.50M |
| June 30, 2020 | 10.80M |
| March 31, 2020 | 10.70M |
| December 31, 2019 | 10.20M |
| September 30, 2019 | 9.30M |
| June 30, 2019 | 9.60M |
| March 31, 2019 | 9.80M |
| December 31, 2018 | 9.80M |
| September 30, 2018 | 10.10M |
| Date | Value |
|---|---|
| June 30, 2018 | 10.80M |
| March 31, 2018 | 9.60M |
| December 31, 2017 | 9.70M |
| September 30, 2017 | 9.10M |
| June 30, 2017 | 10.00M |
| March 31, 2017 | 10.30M |
| December 31, 2016 | 9.60M |
| September 30, 2016 | 9.00M |
| June 30, 2016 | 8.80M |
| March 31, 2016 | 9.40M |
| December 31, 2015 | 10.00M |
| September 30, 2015 | 8.50M |
| June 30, 2015 | 8.10M |
| March 31, 2015 | 7.50M |
| December 31, 2014 | 7.80M |
| September 30, 2014 | 10.80M |
| June 30, 2014 | 9.90M |
| March 31, 2014 | 10.00M |
| December 31, 2013 | 9.70M |
| September 30, 2013 | 9.60M |
| June 30, 2013 | 9.50M |
| March 31, 2013 | 9.10M |
| December 31, 2012 | 8.60M |
| September 30, 2012 | 8.20M |
| June 30, 2012 | 8.20M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
10.20M
Minimum
Dec 2019
18.40M
Maximum
Dec 2023
14.37M
Average
14.10M
Median
Research and Development Expense (Quarterly) Benchmarks
| Repligen Corp | 9.71M |
| Perspective Therapeutics Inc | 9.275M |
| Retractable Technologies Inc | 0.1991M |
| Xtant Medical Holdings Inc | 0.636M |
| Catheter Precision Inc | 0.081M |